Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1387228 | PMC |
| http://dx.doi.org/10.1097/00000658-196801000-00021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Objective: To engineer an acellular mesh to reconstruct the urethra to replace the current surgical practice of using autologous tissue grafts. Cell based approaches have shown progress. However, these have been associated with high costs and logistical challenges.
View Article and Find Full Text PDFDiagnostic status and new explorations in upper urinary tract urothelial carcinoma: a literature review.
Transl Androl Urol
November 2024
Department of Urology, The First People's Hospital of Honghe Prefecture, Gejiu, China.
Background And Objective: Upper urinary tract urothelial carcinomas (UTUCs) are characterized by their obscure location, insidious onset, and propensity for early muscle-invasive and lymph node metastasis, resulting in a generally poor prognosis. Clinically, diagnosis primarily relies on urine cytology, computed tomography urography (CTU), and white light ureteroscopy (WL-URS). These methods, however, suffer from low sensitivity, high cost, inefficient testing, patient discomfort, surgery-related complications, and potential tumor implantation.
View Article and Find Full Text PDFCase report: Toripalimab plus anlotinib in postoperative recurrent renal pelvic sarcomatoid urothelial carcinoma.
Front Oncol
September 2024
Department of General Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Article Synopsis
- Sarcomatoid urothelial carcinoma (SUC) is a rare and aggressive type of kidney cancer with limited treatment options and a poor prognosis.
- A 64-year-old woman initially diagnosed with a kidney stone and urinary infection later underwent surgery revealing advanced SUC, which progressed despite standard chemotherapy.
- The patient achieved a clinical cure after receiving targeted immune therapy combining toripalimab and anlotinib, marking the first reported successful treatment for advanced recurrent SUC in a patient.
Autologous micrografting improves regeneration of tissue-engineered urinary conduits in vivo.
Sci Rep
September 2024
Laboratory of Tissue Engineering, Faculty of Health and Medical Sciences, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Article Synopsis
- * A study was conducted on ten female minipigs, using collagen-based scaffolds with biodegradable mesh, revealing that micrografted scaffolds led to better tissue regeneration than acellular controls after six weeks.
- * The implantation process was successful and safe, with no postoperative complications, suggesting that this method could be a promising option for future urinary conduit surgeries.
Paraneoplastic leukocytosis induces NETosis and thrombosis in bladder cancer PDX model.
Am J Cancer Res
August 2024
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University Taoyuan 33305, Taiwan.
Article Synopsis
- Paraneoplastic leukocytosis (PNL) in genitourinary cancer may signal aggressive disease and poor prognosis, potentially linked to G-CSF and GM-CSF expression in tumors.
- The study created four patient-derived xenograft lines from urothelial cancer, finding that one line (UC-PDX-LN1) had two effective druggable targets and correlated PNL with the patient’s original tumor, suggesting a mechanism of enhanced tumor growth through secreted growth factors.
- The research indicates that combining chemotherapy with interventions targeting neutrophil activity and thrombosis may improve treatment outcomes for bladder cancer patients with PNL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!